医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MEDISCA and Fellow Industry Leaders Lobby for Revisions to Compounded Expiry Dates and Succeed

2021年08月13日 AM06:12
このエントリーをはてなブックマークに追加


 

MASCOT, Australia

Over the last several months, Medisca Australia along with other industry leaders have been actively putting forward to the Australian Pharmaceutical Formulary & Handbook (APF), scientific rationale for longer expiry dates for compounded preparations. Medisca is now pleased to see the efforts of the compounding community come to fruition.

In January 2021, the APF published revised standards where, in the absence of an APF formulary or stability study, compounding pharmacies are restricted to applying up to 28-day expiry dates on all compounded dosage forms, including capsules and powders that have historically received up to 6 months dating. A 28-day expiry date restriction on capsules and powders has the potential to drastically impact compounding pharmacy workflow efficiencies, cost to prepare medications, and most importantly, patient access to much needed personalised medications.

“Upon receiving the news of the change in capsule dating, we quickly ramped up efforts alongside fellow industry leaders and compounding pharmacies to express our concerns to the APF. Not only did the APF listen to us, they acted for us and, ultimately, the patients compounding pharmacy serves,” said Andrew Harb, General Manager for Medisca Australia and Emerging Markets. “The efforts of the last several months demonstrated what it means to be a community – and I and the Medisca team could not be prouder to be a part of it.”

After months of discussions and deliberations, effective as of 10 August 2021, the APF has revised the expiry date of compounded capsules and powders from up to 28 days to up to 6 months. This dating is applicable to capsules and powders that contain ingredients that are stable in air and not hygroscopic or deliquescent. This expiry date guidance is also applicable in the absence of an APF formula or stability study.

For additional support on how to assign an expiry date and access to a databank of stability-indicating studies for extended expiry dating visit: www.medisca.com.au/expiry-date.

About MEDISCA

MEDISCA is the leader in providing turnkey solutions to the pharmaceutical compounding industry and allied health care professionals worldwide. Committed to being a complete resource for prescribers, pharmacists and pharmacy technicians engaged in personalised medicine, MEDISCA offers high quality products, industry-leading support, and first-class education through its partner LP3 Network. Founded in 1989, the company has locations in Canada, the United States and Australia, optimising its service to the international market. For more information about MEDISCA, please visit www.medisca.com.au and follow us on Twitter at @medisca.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005882/en/

CONTACT

Andrew Harb

Unit 7, Heritage Business Park

5-9 Ricketty Street, Mascot

NSW 2020, Australia

Medisca.com.au

1300 786 392

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024